Skip to main content

Table 3 Incidence rate of neutropenia with grade 3 and above

From: Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study

 

Experimental (PK) group

Control (BSA) group

P

Cycle 1

27.52 (30/109)

29.00 (29/100)

0.814

Cycle 2

32.11 (35/109)

32.00 (32/100)

0.986

Cycle 3

36.19 (38/105)

41.30 (38/92)

0.467

Cycle 4

34.07 (31/91)

49.41 (42/85)

0.039

Cycle 5

36.14 (30/83)

56.34 (40/71)

0.012

Cycle 6

38.89 (28/72)

68.33 (41/60)

0.001

  1. Data presented as  % (No. of grade 3 and above AE/Total patients) unless otherwise indicated. AE adverse effects